Earnings & Results
BioSyent Sets November 17 Release for Q3 and Year-to-Date 2026 Financial Results
By News Desk ·
Key takeaways
- BioSyent will report consolidated financial results for the three and nine months ended September 30, 2026 on November 17, 2026 after market hours.
- President and CEO René Goehrum's presentation on the third quarter and year-to-date 2026 results will be available on the company's website on the release date.
- BioSyent had 11,235,488 common shares outstanding as of the November 10, 2026 press release.
BioSyent Inc. will report its consolidated financial results for the three and nine months ended September 30, 2026 on November 17, 2026 after market hours, the company said in a GlobeNewswire release. A presentation on the third quarter and year-to-date 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the company's website on the date of release.
BioSyent's Q3 Release and CEO Presentation
BioSyent is a specialty healthcare products company listed on the TSX Venture Exchange under the symbol RX. It acquires or in-licenses, markets and distributes pharmaceutical and oral health products, operating through Pharmaceutical and Oral Health businesses in Canada and internationally.
The company said the results cover the three and nine months ended September 30, 2026. Goehrum's presentation will be posted on the company's website on the release date, according to the release.
As of the November 10, 2026 press release, BioSyent had 11,235,488 common shares outstanding. The release directs readers to TMX Money for a direct market quote for the TSX Venture Exchange and other company financial information.
BioSyent's Oral Science Deal and Thyconvi Approval
According to akta.pro company records, BioSyent acquired Oral Science Inc., a privately owned Canadian dental hygiene and oral health distributor based in Brossard, Quebec, in March 2026 for $25.5 million in cash, shares and contingent earn-outs through 2033. The same records show FY 2025 revenue of $43.1 million, up 23% year over year, and Q1 2026 revenue of $13.9 million, up 27% year over year.
The records also list FY 2025 EBITDA of $12.1 million, up 30% year over year, and a May 2026 Health Canada approval for Thyconvi (levothyroxine sodium oral solution), which the records describe as the first and only levothyroxine oral solution in Canada, under exclusive BioSyent Pharma license rights.
Earlier BioSyent Results and Health Canada Approval
BioSyent reported consolidated financial results for the second quarter and first half of 2026 on August 20, 2026, driven significantly by the acquisition of Oral Science Inc., according to Yahoo. On August 13, 2026, the Financial Post reported that BioSyent would release those results on August 13, 2026, with a presentation by Goehrum on the company's website.
In May 2026, the Financial Post reported that Health Canada approved Thyconvi (levothyroxine sodium oral solution), making it the first and only levothyroxine oral solution available in Canada for managing hypothyroidism and thyroid-stimulating hormone suppression.
BioSyent's November 17 Results Date
The third quarter and year-to-date 2026 results and Goehrum's presentation are scheduled for November 17, 2026, after market hours.